ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Wednesday.

Other equities analysts have also recently issued research reports about the stock. Cantor Fitzgerald set a $74.00 target price on shares of ANI Pharmaceuticals Inc Common Stock and gave the stock a “buy” rating in a research report on Tuesday, August 7th. BidaskClub cut shares of ANI Pharmaceuticals Inc Common Stock from a “hold” rating to a “sell” rating in a research report on Tuesday. Canaccord Genuity set a $75.00 target price on shares of ANI Pharmaceuticals Inc Common Stock and gave the stock a “buy” rating in a research report on Thursday, August 16th. Finally, Zacks Investment Research cut shares of ANI Pharmaceuticals Inc Common Stock from a “buy” rating to a “hold” rating in a research report on Tuesday, July 10th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. ANI Pharmaceuticals Inc Common Stock presently has a consensus rating of “Hold” and an average price target of $72.67.

ANI Pharmaceuticals Inc Common Stock stock opened at $54.07 on Wednesday. ANI Pharmaceuticals Inc Common Stock has a 52 week low of $49.25 and a 52 week high of $74.70. The company has a current ratio of 3.84, a quick ratio of 2.89 and a debt-to-equity ratio of 1.08. The company has a market cap of $655.10 million, a price-to-earnings ratio of 14.99 and a beta of 2.74.

ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) last posted its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $1.13 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.34 by ($0.21). ANI Pharmaceuticals Inc Common Stock had a return on equity of 27.76% and a net margin of 0.06%. The firm had revenue of $47.27 million for the quarter, compared to the consensus estimate of $50.70 million. sell-side analysts expect that ANI Pharmaceuticals Inc Common Stock will post 4.49 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of ANIP. LSV Asset Management lifted its position in shares of ANI Pharmaceuticals Inc Common Stock by 1,113.5% during the 1st quarter. LSV Asset Management now owns 305,800 shares of the specialty pharmaceutical company’s stock worth $17,803,000 after buying an additional 280,600 shares in the last quarter. BlackRock Inc. raised its holdings in shares of ANI Pharmaceuticals Inc Common Stock by 7.3% in the 2nd quarter. BlackRock Inc. now owns 1,391,174 shares of the specialty pharmaceutical company’s stock worth $92,931,000 after purchasing an additional 94,786 shares during the period. Boston Partners bought a new stake in shares of ANI Pharmaceuticals Inc Common Stock in the 2nd quarter worth approximately $3,144,000. Millennium Management LLC raised its holdings in shares of ANI Pharmaceuticals Inc Common Stock by 1,360.2% in the 1st quarter. Millennium Management LLC now owns 47,544 shares of the specialty pharmaceutical company’s stock worth $2,768,000 after purchasing an additional 44,288 shares during the period. Finally, Avalon Advisors LLC bought a new stake in shares of ANI Pharmaceuticals Inc Common Stock in the 1st quarter worth approximately $2,569,000. 60.68% of the stock is currently owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals Inc Common Stock

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.

Featured Article: What does earnings per share mean?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ANI Pharmaceuticals Inc Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.